

Please amend claims 21 and 22 as follows:

21. (Amended) A composition according to claim 72, wherein the immunostimulant is an adjuvant.

22. (Amended) A composition according to claim 72, wherein the immunostimulant induces a predominantly Type I response.

REMARKS


In response to the Restriction Requirement mailed March 16, 2001, applicants hereby elect the invention of Group I (claims 1-3 and 19-22; drawn to polypeptides, and compositions comprising the polypeptides), and the species of SEQ ID NO: 525 (referred to as P703PDE5). The cDNA sequence encoding SEQ ID NO: 525 is provided in SEQ ID NO: 524.

Claims 1-3, 19 and 20 have been cancelled from the application and rewritten as newly added claims 65-70 in order to remove reference to cancelled species and to focus prosecution on aspects of the invention presently of most commercial interest to the assignee of the subject application. Newly added claims 66-68 are drawn to isolate polypeptides comprising a sequence having either 70%, 90% or 95% identity to SEQ ID NO: 525, wherein the polypeptide is expressed in prostate tissue at levels that are at least twice those found in other normal tissues. Support for newly added claims 66-68 may be found on page 27, lines 1-4, page 36, lines 5-7, and page 110, line 23-26, of the specification as originally filed. It is urged that support for all the above amendments may be found throughout the specification as originally filed, and that none of these amendments constitute new matter.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made."

Early consideration and allowance of the pending claims is respectfully requested.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC


Jeff E. Hundley
Registration No. 42,676

JEP:sds

Enclosure:

Postcard

Check

Petition for an Extension of Time

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

09/483,672

210121.427C11

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 1-3, 19 and 20 have been canceled.

Claims 21 and 22 have been amended as follows:

21. (Amended) A ~~vaccine~~composition according to claim ~~20~~72, wherein the immunostimulant is an adjuvant.

22. (Amended) A ~~vaccine~~composition according to claim ~~20~~72, wherein the immunostimulant induces a predominantly Type I response..